U.S. markets open in 6 hours 33 minutes
  • S&P Futures

    4,156.25
    -6.25 (-0.15%)
     
  • Dow Futures

    33,899.00
    -24.00 (-0.07%)
     
  • Nasdaq Futures

    13,976.25
    -37.75 (-0.27%)
     
  • Russell 2000 Futures

    2,253.40
    -2.30 (-0.10%)
     
  • Crude Oil

    63.67
    +0.21 (+0.33%)
     
  • Gold

    1,762.80
    -4.00 (-0.23%)
     
  • Silver

    25.84
    -0.12 (-0.48%)
     
  • EUR/USD

    1.1965
    -0.0011 (-0.10%)
     
  • 10-Yr Bond

    1.5300
    0.0000 (0.00%)
     
  • Vix

    16.57
    -0.42 (-2.47%)
     
  • GBP/USD

    1.3729
    -0.0055 (-0.40%)
     
  • USD/JPY

    108.8760
    +0.1600 (+0.15%)
     
  • BTC-USD

    61,579.87
    -1,766.10 (-2.79%)
     
  • CMC Crypto 200

    1,364.53
    -16.42 (-1.19%)
     
  • FTSE 100

    6,983.50
    +43.92 (+0.63%)
     
  • Nikkei 225

    29,683.37
    +40.68 (+0.14%)
     

Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

The FDA signed off Flexion Therapeutics Inc's (NASDAQ: FLXN) Phase 1b proof of concept trial evaluating FX301 administered as a popliteal fossa block (a commonly used nerve block in the foot and ankle-related surgeries) in patients undergoing bunionectomy.

  • FX301 combines NaV1.7 inhibitor (funapide) with thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block.

  • The study will start in the first half of this year, with topline data expected in late 2021.

  • The company says that FX301 can potentially provide non-opioid pain relief for at least 3 to 5 days while preserving motor function following musculoskeletal surgery.

  • Preclinical data demonstrated analgesic effect beginning at 1-hour post-dosing compared to placebo and significantly more significant analgesic effect than liposomal bupivacaine at 36 hours post-dosing.

  • Price Action: FLXN shares are 1.4% higher at $11.25 in market trading hours on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.